In the treatment of RET-altered thyroid cancers, the ORRs were 73% and 69%, respectively, in treatment-naïve and previously treated RET-mutant MTCs patients, and 79% in previously treated thyroid cancers patients with RET fusion. The gene discussed is RET; the disease is thyroid gland carcinoma.